Biomea Fusion, Inc. (BMEA)
After hours:
| Previous close | 11.00 |
| Open | 11.27 |
| Bid | 11.62 x 300 |
| Ask | 11.68 x 300 |
| Day's range | 11.13 - 11.88 |
| 52-week range | 8.12 - 43.69 |
| Volume | |
| Avg. volume | 1,003,086 |
| Market cap | 418.755M |
| Beta (5Y monthly) | -0.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.76 |
| Earnings date | 01 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 54.43 |
Simply Wall St.Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
GlobeNewswireBiomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cellsAnnounced initial clinical data from our Phase 2 study (COVALENT-112) in type 1 diabetes from the first two type 1 diabetes patients dosed with BMF-219 and demonstrated ea
- GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on May 1, 2024, the compensation committee of Biomea’s board of directors granted 8 new employees non-qualified stock options to purchase an aggregate of 80,250 shares of th
